Physician profile
Edward Buchsbaum
NPI 1376648170
$1,700.32
in general payments reported to CMS, 2019-2025
16 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $21.23 · 2021: $64.33 · 2022: $124 · 2023: $303 · 2024: $426 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.62 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $400.53 | 2020-2025 | |
| Csl Behring | $300.44 | 2022-2025 | Hizentra |
| Glaxosmithkline, LLC. | $249.19 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $202.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $111.01 | 2021-2025 | Dupixent |
| Alk-Abello, INC | $88.06 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $85.75 | 2021-2023 | Fasenra |
| Genentech USA, INC. | $82.06 | 2019-2023 | Xolair |
| Grifols USA, LLC | $44.31 | 2024-2025 | Xembify |
| Ionis Pharmaceuticals, INC. | $27.31 | 2025 | |
| Biocryst US Sales Co., LLC | $26.94 | 2024 | Orladeyo |
| Aimmune Therapeutics, INC. | $21.61 | 2023 | |
| Phadia US INC. | $15.40 | 2021 | |
| Pfizer INC. | $15.27 | 2023 | |
| Galderma Laboratories, L.P. | $14.98 | 2025 | Nemluvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Buchsbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.